“As new variants emerge with unknown risk, such as the latest omicron, we must continue to research new approaches to ensure that our vaccines can adequately protect against COVID-19,” said Dr. Amy Siegel, internal medicine physician at Austin Regional Clinic and principal investigator at Austin Clinical Research, in a press release.
The trial will look at the safety and efficacy of two boosters, according to the release. One of the boosters will be a multivalent vaccine containing two strains of the virus, and the other is a monovalent vaccine with one strain of the virus.
ARC is the only Central Texas location chosen for the trial, according to the release.
The trial is enrolling adults ages 18-85 who meet certain criteria. More information about participating can be found here.